The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Thyroid Cancer: A Review
Abstract
Importance: Approximately 43 720 new cases of thyroid carcinoma are expected to be diagnosed in 2023 in the US. Five-year relative survival is approximately 98.5%. This review summarizes current evidence regarding pathophysiology, diagnosis, and management of early-stage and advanced thyroid cancer. Observations: Papillary thyroid cancer accounts for approximately 84% of all thyroid cancers. Papillary, follicular (≈4%), and oncocytic (≈2%) forms arise from thyroid follicular cells and are termed well-differentiated thyroid cancer. Aggressive forms of follicular cell-derived thyroid cancer are poorly differentiated thyroid cancer (≈5%) and anaplastic thyroid cancer (≈1%). Medullary thyroid cancer (≈4%) arises from parafollicular C cells. Most cases of well-differentiated thyroid cancer are asymptomatic and detected during physical examination or incidentally found on diagnostic imaging studies. For microcarcinomas (≤1 cm), observation without surgical resection can be considered. For tumors larger than 1 cm with or without lymph node metastases, surgery with or without radioactive iodine is curative in most cases. Surgical resection is the preferred approach for patients with recurrent locoregional disease. For metastatic disease, surgical resection or stereotactic body irradiation is favored over systemic therapy (eg, lenvatinib, dabrafenib). Antiangiogenic multikinase inhibitors (eg, sorafenib, lenvatinib, cabozantinib) are approved for thyroid cancer that does not respond to radioactive iodine, with response rates 12% to 65%. Targeted therapies such as dabrafenib and selpercatinib are directed to genetic mutations (BRAF, RET, NTRK, MEK) that give rise to thyroid cancer and are used in patients with advanced thyroid carcinoma. Conclusions: Approximately 44 000 new cases of thyroid cancer are diagnosed each year in the US, with a 5-year relative survival of 98.5%. Surgery is curative in most cases of well-differentiated thyroid cancer. Radioactive iodine treatment after surgery improves overall survival in patients at high risk of recurrence. Antiangiogenic multikinase inhibitors and targeted therapies to genetic mutations that give rise to thyroid cancer are increasingly used in the treatment of metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee
Tessler, F. N., Middleton, W. D., Grant, E. G., Hoang, J. K., Berland, L. L., Teefey, S. A., Cronan, J. J., Beland, M. D., Desser, T. S., Frates, M. C., et al. (2017) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2017.01.046 · Cited by 2,530
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
Lim, H., Devesa, S. S., Sosa, J. A., Check, D., & Kitahara, C. M. (2017) · JAMA · doi:10.1001/jama.2017.2719 · Cited by 2,159
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Pacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,976
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
Self-citationThyroid Cancer after Exposure to External Radiation: A Pooled Analysis of Seven Studies
Ron, E., Lubin, J. H., Shore, R. E., Mabuchi, K., Modan, B., Pottern, L. M., Schneider, A. B., Tucker, M. A., & Boice, J. D. (1995) · Radiation Research · doi:10.2307/3579003 · Cited by 1,107
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Papillary thyroid microcarcinoma: A study of 900 cases observed in a 60-year period
Hay, I. D., Hutchinson, M. E., Gonzalez-Losada, T., McIver, B., Reinalda, M. E., Grant, C. S., Thompson, G. B., Sebo, T. J., & Goellner, J. R. (2008) · Surgery · doi:10.1016/j.surg.2008.08.035 · Cited by 940
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
An Observational Trial for Papillary Thyroid Microcarcinoma in Japanese Patients
Ito, Y., Miyauchi, A., Inoue, H., Fukushima, M., Kihara, M., Higashiyama, T., Tomoda, C., Takamura, Y., Kobayashi, K., & Miya, A. (2010) · World Journal of Surgery · doi:10.1007/s00268-009-0303-0 · Cited by 811
Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
Wirth, L. J., Sherman, E., Robinson, B., Solomon, B., Kang, H., Lorch, J., Worden, F., Brose, M., Patel, J., Leboulleux, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005651 · Cited by 790
Self-citationBible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0944 · Cited by 730
Self-citationOutcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy
Jonklaas, J., Sarlis, N. J., Litofsky, D., Ain, K. B., Bigos, S. T., Brierley, J. D., Cooper, D. S., Haugen, B. R., Ladenson, P. W., Magner, J., et al. (2006) · Thyroid · doi:10.1089/thy.2006.16.1229 · Cited by 695
Nguyen, B., Fong, C., Luthra, A., Smith, S. A., DiNatale, R. G., Nandakumar, S., Walch, H., Chatila, W. K., Madupuri, R., Kundra, R., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.003 · Cited by 623
Risk of Thyroid Cancer After Exposure to 131 I in Childhood
Cardis, E., Kesminiene, A., Ivanov, V., Malakhova, I., Shibata, Y., Khrouch, V., Drozdovitch, V., Maceika, E., Zvonova, I., Vlassov, O., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji129 · Cited by 591
Haymart, M. R., Repplinger, D. J., Leverson, G. E., Elson, D. F., Sippel, R. S., Jaume, J. C., & Chen, H. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2215 · Cited by 499
Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance
Tuttle, R. M., Fagin, J. A., Minkowitz, G., Wong, R. J., Roman, B., Patel, S., Untch, B., Ganly, I., Shaha, A. R., Shah, J. P., et al. (2017) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2017.1442 · Cited by 484
Self-citationChakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X.-H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46382 · Cited by 391
Rothenberg, S. M., McFadden, D. G., Palmer, E. L., Daniels, G. H., & Wirth, L. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2915 · Cited by 376
The 2023 Bethesda System for Reporting Thyroid Cytopathology
Ali, S. Z., Baloch, Z. W., Cochand-Priollet, B., Schmitt, F. C., Vielh, P., & VanderLaan, P. A. (2023) · Thyroid® · doi:10.1089/thy.2023.0141 · Cited by 368
Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00120-0 · Cited by 366
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C. C., Cabanillas, M. E., Boran, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.014 · Cited by 357
Self-citationCOOPER, D. S., SPECKER, B., HO, M., SPERLING, M., LADENSON, P. W., ROSS, D. S., AIN, K. B., BIGOS, S. T., BRIERLEY, J. D., HAUGEN, B. R., et al. (1998) · Thyroid · doi:10.1089/thy.1998.8.737 · Cited by 353
Yoo, S.-K., Lee, S., Kim, S.-J., Jee, H.-G., Kim, B.-A., Cho, H., Song, Y. S., Cho, S. W., Won, J.-K., Shin, J.-Y., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006239 · Cited by 349
Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update
Wells, S. A., Pacini, F., Robinson, B. G., & Santoro, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1204 · Cited by 338
Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2017) · JAMA · doi:10.1001/jama.2017.4011 · Cited by 313
Papillary Thyroid Cancer: Time Course of Recurrences During Postsurgery Surveillance
Durante, C., Montesano, T., Torlontano, M., Attard, M., Monzani, F., Tumino, S., Costante, G., Meringolo, D., Bruno, R., Trulli, F., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3401 · Cited by 310
Biondi, B., & Cooper, D. S. (2010) · Thyroid · doi:10.1089/thy.2009.0311 · Cited by 286
Fugazzola, L., Elisei, R., Fuhrer, D., Jarzab, B., Leboulleux, S., Newbold, K., & Smit, J. (2019) · European Thyroid Journal · doi:10.1159/000502229 · Cited by 285
Ganly, I., Makarov, V., Deraje, S., Dong, Y., Reznik, E., Seshan, V., Nanjangud, G., Eng, S., Bose, P., Kuo, F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.002 · Cited by 283
Gopal, R. K., Kübler, K., Calvo, S. E., Polak, P., Livitz, D., Rosebrock, D., Sadow, P. M., Campbell, B., Donovan, S. E., Amin, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.013 · Cited by 263
Brose, M. S., Robinson, B., Sherman, S. I., Krajewska, J., Lin, C.-C., Vaisman, F., Hoff, A. O., Hitre, E., Bowles, D. W., Hernando, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00332-6 · Cited by 256
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Dunn, L. A., Sherman, E. J., Baxi, S. S., Tchekmedyian, V., Grewal, R. K., Larson, S. M., Pentlow, K. S., Haque, S., Tuttle, R. M., Sabra, M. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01478 · Cited by 250
Self-citationTronko, M. D., Howe, G. R., Bogdanova, T. I., Bouville, A. C., Epstein, O. V., Brill, A. B., Likhtarev, I. A., Fink, D. J., Markov, V. V., Greenebaum, E., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj244 · Cited by 245
Thyroid Cancer in the Pediatric Population
Paulson, V. A., Rudzinski, E. R., & Hawkins, D. S. (2019) · Genes · doi:10.3390/genes10090723 · Cited by 242
Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M. C., Niederle, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx479 · Cited by 240
Ciampi, R., Romei, C., Ramone, T., Prete, A., Tacito, A., Cappagli, V., Bottici, V., Viola, D., Torregrossa, L., Ugolini, C., et al. (2019) · iScience · doi:10.1016/j.isci.2019.09.030 · Cited by 239
Impact on Overall Survival of Radioactive Iodine in Low-Risk Differentiated Thyroid Cancer Patients
Schvartz, C., Bonnetain, F., Dabakuyo, S., Gauthier, M., Cueff, A., Fieffé, S., Pochart, J.-M., Cochet, I., Crevisy, E., Dalac, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2512 · Cited by 231
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer
Leboulleux, S., Bournaud, C., Chougnet, C. N., Zerdoud, S., Al Ghuzlan, A., Catargi, B., Do Cao, C., Kelly, A., Barge, M.-L., Lacroix, L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2111953 · Cited by 228
Demetri, G. D., De Braud, F., Drilon, A., Siena, S., Patel, M. R., Cho, B. C., Liu, S. V., Ahn, M.-J., Chiu, C.-H., Lin, J. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3597 · Cited by 223
Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer
Hadoux, J., Elisei, R., Brose, M. S., Hoff, A. O., Robinson, B. G., Gao, M., Jarzab, B., Isaev, P., Kopeckova, K., Wadsley, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2309719 · Cited by 210
Lamartina, L., Durante, C., Filetti, S., & Cooper, D. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3882 · Cited by 196
Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident
Morton, L. M., Karyadi, D. M., Stewart, C., Bogdanova, T. I., Dawson, E. T., Steinberg, M. K., Dai, J., Hartley, S. W., Schonfeld, S. J., Sampson, J. N., et al. (2021) · Science · doi:10.1126/science.abg2538 · Cited by 169
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
Waguespack, S. G., Drilon, A., Lin, J. J., Brose, M. S., McDermott, R., Almubarak, M., Bauman, J., Casanova, M., Krishnamurthy, A., Kummar, S., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1259 · Cited by 168
Self-citationTargeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine
Jaber, T., Waguespack, S. G., Cabanillas, M. E., Elbanan, M., Vu, T. H., Dadu, R., Sherman, S. I., Amit, M., Santos, E. B., Zafereo, M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00612 · Cited by 146
Self-citationCabanillas, M. E., & Takahashi, S. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.11.004 · Cited by 141
Self-citationLorenz, K., Raffaelli, M., Barczyński, M., Lorente-Poch, L., & Sancho, J. (2020) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-020-01907-x · Cited by 140
Busaidy, N. L., Konda, B., Wei, L., Wirth, L. J., Devine, C. E., Daniels, G. A., DeSouza, J. A., Poi, M. J., Seligson, N. D., Cabanillas, M. E., et al. (2022) · Thyroid · doi:10.1089/thy.2022.0115 · Cited by 139
Self-citationIravani, A., Solomon, B., Pattison, D. A., Jackson, P. A., Kumar, A. S. R., Kong, G., Hofman, M. S., Akhurst, T. J., & Hicks, R. J. (2019) · Thyroid · doi:10.1089/thy.2019.0143 · Cited by 127
Zhao, X. L., Wang, J. R., Dadu, R., Busaidy, N. L., Xu, L., Learned, K. O., Chasen, N. N., Vu, T. H., Maniakas, A., Eguia, A. A., et al. (2023) · Thyroid · doi:10.1089/thy.2022.0504 · Cited by 120
Self-citationRAS proto-oncogene in medullary thyroid carcinoma
Moura, M. M., Cavaco, B. M., & Leite, V. A. P. H. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0070 · Cited by 119
Benign Thyroid Diseases and Risk of Thyroid Cancer: A Nationwide Cohort Study
Kitahara, C. M., Farkas, D. K., Jørgensen, J. O. L., Cronin-Fenton, D. P., & Sørensen, H. T. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02599 · Cited by 114
The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers
Leboulleux, S., Schroeder, P. R., Schlumberger, M. J., & Ladenson, P. W. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0402 · Cited by 109
Leboulleux, S., Cao, C. D., Zerdoud, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0046 · Cited by 107
Malignancy rates in thyroid nodules: a long-term cohort study of 17,592 patients
Grußendorf, M., Ruschenburg, I., & Brabant, G. E. (2022) · European Thyroid Journal · doi:10.1530/etj-22-0027 · Cited by 104
Nicolson, N. G., Murtha, T. D., Dong, W., Paulsson, J. O., Choi, J., Barbieri, A. L., Brown, T. C., Kunstman, J. W., Larsson, C., Prasad, M. L., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00277 · Cited by 96
Kim, D. H., Kim, S. W., Basurrah, M. A., Lee, J., & Hwang, S. H. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.22.28556 · Cited by 94
Pathogenesis of cancers derived from thyroid follicular cells
Fagin, J. A., Krishnamoorthy, G. P., & Landa, I. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00598-y · Cited by 94
Radioiodine Therapy in Patients with Stage I Differentiated Thyroid Cancer
Jonklaas, J., Cooper, D. S., Ain, K. B., Bigos, T., Brierley, J. D., Haugen, B. R., Ladenson, P. W., Magner, J. A., Ross, D. S., Skarulis, M. C., et al. (2010) · Thyroid · doi:10.1089/thy.2010.0308 · Cited by 92
Nies, M., Vassilopoulou‐Sellin, R., Bassett, R. L., Yedururi, S., Zafereo, M., Cabanillas, M. E., Sherman, S. I., Links, T. P., & Waguespack, S. G. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa935 · Cited by 87
Self-citationMolecular Genetics of Thyroid Cancer in Children and Adolescents
Bauer, A. J. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.01.014 · Cited by 85
Grani, G., Zatelli, M. C., Alfò, M., Montesano, T., Torlontano, M., Morelli, S., Deandrea, M., Antonelli, A., Francese, C., Ceresini, G., et al. (2020) · Thyroid · doi:10.1089/thy.2020.0272 · Cited by 85
Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets
Cerrato, A., Falco, V. D., & Santoro, M. (2009) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0024 · Cited by 82
Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma
Wang, J. R., Montierth, M. D., Li, X., Goswami, M., Zhao, X. L., Cote, G. J., Wang, W., Iyer, P. C., Dadu, R., Busaidy, N. L., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00504 · Cited by 76
Self-citationChiosea, S. I., Hodak, S. P., Yip, L., Abraham, D., Baldwin, C. K., Baloch, Z. W., Güleç, S., Hannoush, Z. C., Haugen, B. R., Joseph, L., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad220 · Cited by 67
Sajisevi, M. B., Caulley, L., Eskander, A. E., Du, Y., Auh, E., Karabachev, A. D., CALLAS, P. W., Conradie, W., Martin, L. I., Pasternak, J. D., et al. (2022) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2022.1743 · Cited by 65
Self-citationDedhia, P. H., Saucke, M. C., Long, K. L., Doherty, G. M., & Pitt, S. C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8722 · Cited by 45
Posthemithyroidectomy Hypothyroidism: Updated Meta-Analysis of Risk Factors and Rates of Remission
Apostolou, K. G., Paunovic, I. R., Frountzas, M., Zivaljevic, V. R., Tausanovic, K. M., Karanikas, M., Koutelidakis, I. M., & Schizas, D. (2023) · Journal of Surgical Research · doi:10.1016/j.jss.2023.08.020 · Cited by 19
Stevens, A., Meier, J., Bhat, A., et al. (2023) · Surgery · doi:10.1016/j.surg.2023.05.033 · Cited by 8
Metadata
- Authors
- Boucai, L., Zafereo, M., & Cabanillas, M. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2024-02-06
- Volume
- 331
- Issue
- 5
- Pages
- 425
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4391562669
- Cited by
- 701
- References
- 76
- FWCI
- 190.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.